Consolidation strategies in ovarian cancer: observations for future clinical trials.
about
Immunotherapy for ovarian cancer: what's next?Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remissionOpportunities in immunotherapy of ovarian cancer.Health-related quality of life in ovarian cancer patients and its impact on clinical managementAdjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
P2860
Consolidation strategies in ovarian cancer: observations for future clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@en
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@nl
type
label
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@en
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@nl
prefLabel
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@en
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@nl
P2093
P2860
P1433
P1476
Consolidation strategies in ovarian cancer: observations for future clinical trials.
@en
P2093
Alexia Iasonos
Carol Aghajanian
David Spriggs
Kathryn Bell-McGuinn
Margrit Juretzka
Martee Hensley
Paul Sabbatini
William Tew
P2860
P356
10.1016/J.YGYNO.2009.09.016
P407
P50
P577
2010-01-01T00:00:00Z